SARM / PPARδ Agonist

Cardarine (GW-501516)

PPARδ agonist (NOT technically a SARM). Dramatically improves endurance and fat oxidation. ⚠️ CRITICAL WARNING: Abandoned by GSK after promoting dose-dependent tumour growth at ALL doses tested in rodent carcinogenicity studies.

Build protocol outline Open dose calculator TNHL ebooks

Educational reference only. This page does not diagnose, prescribe, or replace care from a licensed professional. Laws, availability, and clinical appropriateness vary by location.

Reference dose10–20 mg/day (research — high risk)

Half-life24 hours

Risk flagextreme

Regulatory noteResearch-only flag

Side effects and watch-outs

⚠️⚠️ CANCER WARNING: Promoted tumour growth at ALL doses tested in 2-year rodent studies
⚠️ Phase 2 trials DELIBERATELY HALTED by developer (GSK) due to cancer findings
⚠️ Many researchers and physicians advise against ANY human use
Rhabdomyolysis (rare, high dose)
Well tolerated short-term — does NOT mean safe
⚠️ This compound was abandoned by its creator specifically due to carcinogenicity concerns